

ReLink – set to reshape the IV industry



EIC Accelerator grant
Fast Track to Innovation grant
Eurostars-2 grant

The project has received funding from the European Union's Horizon 2020 research and innovation programme under EIC Accelerator grant agreement No 961967, Fast Track to Innovation grant No 971225 and from the Eurostars-2 Joint Programme with co-funding from the European Union's Horizon 2020 research and innovation programme.




IV therapy has a failure rate of over 40%

16bn IV lines used annually



along with over 1.5bn IV catheters



40% failures caused by harmful forces on the IV line

Global disastrous consequences



Safety consequences

- Patient injury and risk of death
- Toxic exposure and increased cancer risk for healthcare personnel
- Loss of medication & interrupted treatment



Economic consequences

- 30 minutes of nursing time wasted per incident
- 23K tonnes of plastic waste per year
- €72bn in unnecessary annual healthcare costs*

ReLink

Breakaway connector


Weak link catheter protection

Self-sealing valves


Preventing leakage

Reconnectable

Rapid therapy restart



ReLink technology : Radical reduction in the risk and consequences of IV failure



Competitive landscape



ReLink delivers radically superior performance over all the other options

ReLink's clear competitive advantage		ReLink	Traditional securement devices		Engineered stabilisation devices		Other Breakaway connectors	
			Tape & Gauze	Sutures	Grip-lok / StatLock	SecurAcath	SafeBreak	Orchid SRV
Superior management of IV line	Dislodgement rate	<1% ¹	10% average ²		5-6%	<2%	~3% ³	Not published
	Add on feature - Reconnectable, rapid reinstatement of therapy	●	●	●	●	●	●	●
	Prevents exposure to hazardous fluids and vapours	●	●	●	●	●	●	●
	Prevents plastic & medical waste	●	●	●	●	●	●	●
Reduced complication	Non-invasive - no risk for MARSI*	●	●	●	●	●	●	●
Easy to adopt	No additional training required for healthcare professionals	●	●	●	●	●	●	●
	One size fits all	●	●	●	●	●	●	●

Legend	●	●	●
	Meets completely	Partially meets	Does not meet

*MARSI – Medical adhesives related skin injury/ infection

ReLink complements traditional solutions to deliver an unmatched proposition



Full spectrum of catheter movement issues addressed

Lower range forces

Traditional solutions



- Antimicrobial protection
- Securement
- Bacterial and viral barrier



High range forces

ReLink platform

- Dislodgement prevention
- Minimised consequences
- Reconnectable and efficient




Improved clinical outcomes


Safer patients and nurses

Improved economics

Direct economic benefits for the hospitals




Relink's proposition makes three market segments highly attractive




These segments represent a collective opportunity of over 6bn tubes annually



6.5bn tubes annually – the opportunity for ReLink



These segments represent a collective opportunity of over 6Bn tubes annually



Demand drivers for ReLink

Scale

16bn IV lines
every year

23K tonnes
of plastic waste

Chronic Shortage


Shortage of
nursing staff

Shortage of
medicine

Chronic nursing shortage, globally

Global nursing shortage is a compelling driver for ReLink

Nursing capacity by country, per 1000 people



Risk reduction & growing market access

Over the years we have invested in tangible and intangible assets which reduce risk for our investors and improve market access for the ReLink technology.

1

A competent team

2

Patents and regulatory approvals

3

Direct sales to hospitals

4

Market traction

5

Clinical trials underway

The team : we are well-equipped to bring ReLink to the global market

1

Winning team



Chief Quality Officer



Chief Financial Officer



Chief Strategy Officer



Design Manager



HEOR & RWE Manager



Finance Controller



R&D Engineer



R&D Engineer



Katarina Hedbeck
CEO & Co-founder



Dr. Rebecca Bejhed
COO & Co-founder



Christopher Blacker, MD
Medical Lead
& Co-founder



Andreas Dahlen
Board Member



Antonio Sanchez-Cordero
Board Member

Patents and regulatory approvals provide us the foundation for commercialisation

2

Patent approved in



Europe



U.S.A



Russia



Australia



Egypt



Indonesia



China



South Korea



South Africa



Israel



Japan



Malaysia



Mexico

+ additional patents in pipeline

Regulatory approvals

CE mark approved



ISO 13485 certified



Market traction : ReLink is now on patients and we continue to expand our presence

3



Direct to hospital sales



Currently in active sales discussions with global MedTech giants

4



Live on humans and animals across EU and USA



Clinical trials : Three ongoing for human and veterinary patients

5

Clinical trials

ReLink (Veterinary)

Sweden



USA



ReLink (Class Is)

Sweden



ReLink (Class IIa)


Spain



Portugal



Strategic market selection: balancing scale and high margin potential for Relink's global expansion



Our route to market



- **Direct to hospitals**
- **Partnership with global MedTech co**




The ReLink edge for our partners

ReLink activates profitable growth for our partners:



Advancing towards market success: our journey and milestones


Funding source : 50% soft loans and 50% equity



The clear path ahead: Going global


The large global opportunity

- 16bn IV lines
- Global chronic shortage



Internal capacities needed to unlock full potential of 16bn IV lines

Exit opportunities for investors: M&A and IPO



Following similar acquisitions in the industry:


- BD acquired Carmel Pharma for \$287mn
- ICU Medical acquired Pursuit Vascular Inc for \$75mn + earn-out payment

5-year financial projections




Volumes

All numbers in mn pieces



Revenue

All numbers in mn Euro



Raising €6,5mn

Investments in tools and machines

to scale and reduce per unit manufacturing cost to under €1

Commercial expansion

in identified markets , working with global players and regional distributors

New product development

to expand ReLink applications to new market segments such as dialysis and blood transfusions

Thank you

Contact

Katarina Hedbeck

CEO & Co-founder

Katarina.hedbeck@tadagroup.se

+46 702206500

www.tadagroup.se



References



- ¹ Bejhed, R. S. CN23 Increased patient and occupational safety for home infusion of cytotoxic and other hazardous drugs. Ann. Oncol. 31, S1132 (2020).
- ² Literature study
- ³ Panza, G. A., Steere, L., & Steinberg, A. C. (2022). A New Force-Activated Separation Device for the Prevention of Peripheral Intravenous Restarts. Journal of Infusion Nursing, 45(2), 74-80. <https://doi.org/10.1097/NAN.0000000000000455>
- ⁴ Sources for nursing capacity per capita
 - Data.worldbank.org, Latest available data
 - Stats And Facts On The UK's Nursing Workforce 2023, <https://www.nurses.co.uk/> reviewed on 5th Sep 2023
 - McKinsey report dated May 11, 2022 "Assessing the lingering impact of COVID-19 on the nursing workforce"